Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Ter Heine

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Cancer Chemotherapy and Pharmacology|November 6, 2025
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicityRob Ter Heine, Bianca J C van den Bosch, Robin M van Geel, et al.
The Lancet. Microbe|January 14, 2022
Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent <i>Plasmodium falciparum</i> malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trialWilliam Stone, Almahamoudou Mahamar, Koualy Sanogo, et al.
Cancer Chemotherapy and Pharmacology|June 29, 2020
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX studyLoek A W de Jong, Fortuné M K Elekonawo, Marie Lambert, et al.
International Journal of Cancer|June 28, 2021
Toxicity of pemetrexed during renal impairment explained-Implications for safe treatmentRené J Boosman, Thomas P C Dorlo, Nikki de Rouw, et al.
Clinical Pharmacokinetics|July 25, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic EvaluationFenna de Vries, Eric J F Franssen, Arthur A J Smit, et al.
European Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)Joanneke K Overbeek, Niels A D Guchelaar, Ma Ida Mohmaed Ali, et al.
International Journal of Pharmaceutics|February 25, 2014
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastasesRob ter Heine, Rogier Lange, Oscar B Breukels, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2022
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trialNikki de Rouw, René J Boosman, Jacobus A Burgers, et al.
The Lancet. Microbe|May 5, 2024
Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, MaliAlmahamoudou Mahamar, Merel J Smit, Koualy Sanogo, et al.
Trials|June 24, 2020
Correction to: Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trialsThijs Ten Doesschate, Simone J C F M Moorlag, Thomas W van der Vaart, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|November 6, 2025
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicityRob Ter Heine, Bianca J C van den Bosch, Robin M van Geel, et al.
The Lancet. Microbe|January 14, 2022
Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent <i>Plasmodium falciparum</i> malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trialWilliam Stone, Almahamoudou Mahamar, Koualy Sanogo, et al.
Cancer Chemotherapy and Pharmacology|June 29, 2020
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX studyLoek A W de Jong, Fortuné M K Elekonawo, Marie Lambert, et al.
International Journal of Cancer|June 28, 2021
Toxicity of pemetrexed during renal impairment explained-Implications for safe treatmentRené J Boosman, Thomas P C Dorlo, Nikki de Rouw, et al.
Clinical Pharmacokinetics|July 25, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic EvaluationFenna de Vries, Eric J F Franssen, Arthur A J Smit, et al.
European Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)Joanneke K Overbeek, Niels A D Guchelaar, Ma Ida Mohmaed Ali, et al.
International Journal of Pharmaceutics|February 25, 2014
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastasesRob ter Heine, Rogier Lange, Oscar B Breukels, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2022
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trialNikki de Rouw, René J Boosman, Jacobus A Burgers, et al.
The Lancet. Microbe|May 5, 2024
Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, MaliAlmahamoudou Mahamar, Merel J Smit, Koualy Sanogo, et al.
Trials|June 24, 2020
Correction to: Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trialsThijs Ten Doesschate, Simone J C F M Moorlag, Thomas W van der Vaart, et al.
Pageof 16